Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus

References

• Gaipl US, Voll RE, Sheriff A, et al. Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev. 2005;4:189–194.
   PubMed Web of Science ®Google Scholar
• Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521–530.
   PubMed Web of Science ®Google Scholar
• Song IH, Buttgereit F. Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol. 2006;246:142–146.
   PubMed Web of Science ®Google Scholar
• Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168–1172.
   PubMed Web of Science ®Google Scholar
• Avalos AM, Busconi L, Marshak-Rothstein A. Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity. 2010;43:76–83.
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416:603–607.
   PubMed Web of Science ®Google Scholar
• Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005;202:1171–1177.
   PubMed Web of Science ®Google Scholar
• Venkatesh J, Kawabata D, Kim S, et al. Selective regulation of autoreactive B cells by FcgammaRIIB. J Autoimmun. 2009;32:149–157.
   PubMed Web of Science ®Google Scholar
• Tchorbanov AI, Voynova EN, Mihaylova NM, et al. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur J Immunol. 2007;37:3587–3596.
   PubMed Web of Science ®Google Scholar
• Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2012;127:303–312.
   Web of Science ®Google Scholar
• Dolff S, Bijl M, Huitema MG, et al. Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin Immunol. 2011;141:197–204.
   PubMed Web of Science ®Google Scholar
• Shah K, Lee WW, Lee SH, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:R53.
   PubMed Web of Science ®Google Scholar
• Reiner SL. Development in motion: helper T cells at work. Cell. 2007;129:33–36.
   PubMed Web of Science ®Google Scholar
• Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008;8:337–348.
   PubMed Web of Science ®Google Scholar
• Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001;166:2913–2916.
   PubMed Web of Science ®Google Scholar
• Lim LHK, Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J. 2007;21:968–975.
   PubMed Web of Science ®Google Scholar
• Perretti M, D’Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol. 2009;9:62–70.
   PubMed Web of Science ®Google Scholar
• Spurr L, Nadkarni S, Pederzoli-Ribeil M, et al. Comparative analysis of Annexin A1-formyl peptide receptor 2/ALX expression in human leukocyte subsets. Int Immunopharmacol. 2011;11:55–66.
   PubMed Web of Science ®Google Scholar
• D’Acquisto F, Perretti M, Flower RJ. Annexin-A1: a pivotal regulator of the innate and adaptive immune systems. Br J Pharmacol. 2008;155:152–169.
   PubMed Web of Science ®Google Scholar
• Pederzoli-Ribeil M, Maione F, Cooper D, et al. Design and characterization of a cleavage-resistant Annexin A1 mutant to control inflammation in the microvasculature. Blood. 2010;116:4288–4296.
   PubMed Web of Science ®Google Scholar
• D’Acquisto F, Paschalidis N, Sampaio ALF, et al. Impaired T cell activation and increased Th2 lineage commitment in Annexin-1-deficient T cells. Eur J Immunol. 2007;37:3131–3142.
   PubMed Web of Science ®Google Scholar
• Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004;363:1869–1870.
   PubMed Web of Science ®Google Scholar
• Vishwanatha JK, Salazar E, Gopalakrishnan VK. Absence of annexin I expression in B-cell non-Hodgkin's lymphomas and cell lines. BMC Cancer. 2004;4:8.
   PubMed Web of Science ®Google Scholar
• Felicity N, Gavins E, Hickey MJ. Annexin A1 and the regulation of innate and adaptive immunity. Front Immunol. 2012;3:354. doi:10.3389/fimmu.2012.00354.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Levin NA. ‘ASIA’ – Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4–8.
   PubMed Web of Science ®Google Scholar
• Dimitrova I, Gesheva V, Nikolova K, et al. Target silencing of disease-associated B-lymphocytes by chimeric molecules in SCID model of pristane-induced autoimmunity. Lupus. 2010;19:1261–1271.
   PubMed Web of Science ®Google Scholar
• Papp K, Végh P, Tchorbanov A, et al. Progression of lupus-like disease drives the appearance of complement-activating IgG antibodies in MRL/lpr mice. Rheumatology (Oxford) 2010;49:2273–2280.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Cutler AJ, Brownlie RJ, et al. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol. 2007;8:419–429.
   PubMed Web of Science ®Google Scholar
• Mei HE, Schmidt S, Dörner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther. 2012;14:S1.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215–1226.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73:183–190.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Sanz I, Bosch, X, et al. B-cell-depleting therapy in systemic lupus erythematosus. Am J Med. 2012;125:327–336.
   PubMed Web of Science ®Google Scholar
• Tarasenko T, Dean JA, Bolland S. FcgammaRIIB as a modulator of autoimmune disease susceptibility. Autoimmunity. 2007;40:409–417.
   PubMed Web of Science ®Google Scholar
• Gesheva V, Kerekov N, Nikolova K, et al. Suppression of dsDNA-specific B lymphocytes reduces disease symptoms in SCID model of mouse lupus. Autoimmunity. 2014;647:162–172.
   PubMed Web of Science ®Google Scholar
• Freed JH, Marrs A, Vander Wall J, et al. MHC class II-bound self peptides from autoimmune MRL/lpr mice reveal potential T cell epitopes for autoantibody production in murine systemic lupus erythematosus. J Immunol. 2000;164:4697–4705.
   PubMed Web of Science ®Google Scholar
• Foster MH. T cells and B cells in lupus nephritis. Semin Nephrol. 2007;27:47–58.
   PubMed Web of Science ®Google Scholar
• Crispin JC, Kyttaris VC, Terhorst C, et al. T cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6:317–325.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:3077–3087.
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Gilroy DW, Solito E, et al. Attenuation of glucocorticoid functions in an Anx-A1-/- cell line. Biochem J. 2003;371:927–935.
   PubMed Web of Science ®Google Scholar
• Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82:331–371.
   PubMed Web of Science ®Google Scholar
• Yang YH, Morand E, Leech M. Annexin A1: potential for glucocorticoid sparing in RA. Nat Rev Rheumatol. 2013;9:595–603.
   PubMed Web of Science ®Google Scholar
• Paschalidis N, Iqbal AJ, Maione F, et al. Modulation of experimental autoimmune encephalomyelitis by endogenous annexin A1. J Neuroinflammation. 2009;6:33.
   PubMed Web of Science ®Google Scholar
• Rescher U, Danielczyk A, Markoff A, et al. Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells1. J Immunol. 2002;169:1500–1504.
   PubMed Web of Science ®Google Scholar
• D’Acquisto F. On the adaptive nature of Annexin-A1. Curr Opin Pharmacol. 2009;9:521–528.
   PubMed Web of Science ®Google Scholar
• Panaro MA, Acquafredda A, Sisto M, et al. Biological role of the N-formyl peptide receptors. Immunopharmacol Immunotoxicol. 2006;28:103–127.
   PubMed Web of Science ®Google Scholar
• Yona S, Heinsbroek SE, Peiser L, et al. Impaired phagocytic mechanism in annexin 1 null macrophages. Br J Pharmacol. 2006;148:469–477.
   PubMed Web of Science ®Google Scholar
• Kamal AM, Smith SF, De Silva Wijayasinghe M, et al. An annexin 1 (ANXA1)-derived peptide inhibits prototype antigen-driven human T cell Th1 and Th2 responses in vitro. Clin Exp Allergy. 2001;31:1116–1125.
   PubMed Web of Science ®Google Scholar
• Yang YH, Song W, Deane JA, et al. Deficiency of annexin A1 in CD4+ T cells exacerbates T cell-dependent inflammation. J Immunol. 2013;190:997–1007.
   PubMed Web of Science ®Google Scholar
• D’Acquisto F, Merghani A, Lecona E, et al. Annexin-1 modulates T-cell activation and differentiation. Blood. 2007;109:1095–1102.
   PubMed Web of Science ®Google Scholar
• D’Acquisto F, Piras G, Rattazzi L. Pro-inflammatory and pathogenic properties of Annexin-A1: the whole is greater than the sum of its parts. Biochem Pharmacol. 2013;85:1213–1218.
   PubMed Web of Science ®Google Scholar
• Bruschi M, Sinico RA, Moroni G, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI. J Am Soc Nephrol. 2014;25:2483–2498.
   PubMed Web of Science ®Google Scholar
• Belvedere R, Bizzarro V, Forte G, et al. Annexin A1 contributes to pancreatic cancer cell phenotype, behaviour and metastatic potential independently of Formyl Peptide Receptor pathway. Sci Rep. 2016;6:Article ID:29660.
   PubMed Web of Science ®Google Scholar
• Bist P, Leow SC, Phua QH, et al. Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-κB: implication in breast cancer metastasis. Oncogene. 2011;30:3174–3185.
   PubMed Web of Science ®Google Scholar
• Huston DP, Steinberg AD. Animal models of human systemic lupus erythematosus. Yale J Biol Med. 1979;52:289–305.
   PubMed Web of Science ®Google Scholar
• Andersson Å, Holmdahl R. A genetic basis for shared autoimmunity in mouse models. Autoimmunity. 2005;38:209–217.
   PubMed Web of Science ®Google Scholar
• Herman S, Kny A, Schorn C, et al. Cell death and cytokine production induced by autoimmunogenic hydrocarbon oils. Autoimmunity. 2012;45:602–611.
   PubMed Web of Science ®Google Scholar
• Chae BS, Shin TY. Immunoregulatory abnormalities of T cells and hyperreactivity of B cells in the in vitro immune response in pristane-induced lupus mice. Arch Pharm Res. 2007;30:191–198.
   PubMed Web of Science ®Google Scholar
• Reeves WH, Lee PY, Weinstein JS, et al. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009;30:455–464.
   PubMed Web of Science ®Google Scholar
• Kyttaris VC, Juang YT, Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2005;17:518–522.
   PubMed Web of Science ®Google Scholar
• Perry D, Sang A, Yin Y, et al. Murine models of systemic lupus erythematosus. J Biomed Biotechnol. 2011;2011: Article ID: 271694.
   PubMedGoogle Scholar
• Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003;8:223–246.
   PubMedGoogle Scholar
• O’Shea J, Ma A, Lipski P. Cytokines and autoimmunity. Nat Rev. 2001;2:37–45.
   Google Scholar
• Bobe P, Bonardelle D, Benihoud K, et al. Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood. 2006;108:3967–3975.
   PubMed Web of Science ®Google Scholar
• Gesheva V, Szekeres Z, Mihaylova N, et al. Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases. Hum Gene Ther Methods. 2012;23:357–365.
   PubMed Web of Science ®Google Scholar
• La Cava A. Anticytokine therapies in systemic lupus erythematosus. Immunotherapy. 2010;2:575–582.
   PubMed Web of Science ®Google Scholar